Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
Alzheimers Dement. 2012 Jul;8(4):337-42. doi: 10.1016/j.jalz.2012.04.007.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2003 to speed drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public-private partnership, the first phase of ADNI (ADNI 1) set a new standard for data sharing without embargo. In addition, it has been extended to 2017 by additional funding (North American-ADNI Grand Opportunities and ADNI 2) as well as multiple projects around the world, collectively known as Worldwide ADNI (WW-ADNI). The goal of WW-ADNI is to harmonize projects and results across different geographical sites and to encourage and harmonize data management and availability to investigators around the world. WW-ADNI projects are currently underway in North America, Europe, Japan, Australia, Korea, Taiwan, and Argentina, with a nascent program in China and a possible future program in Brazil.
阿尔茨海默病神经影像学倡议（ADNI）成立于 2003 年，旨在通过验证阿尔茨海默病临床治疗试验的影像学和血液/脑脊液生物标志物来加速药物开发。ADNI 是一项自然（非治疗）多站点纵向研究。作为真正的公私合作伙伴关系，ADNI 的第一阶段（ADNI1）为无限制的数据共享设定了新的标准。此外，通过额外的资金（北美-ADNI 大机遇和 ADNI2）以及世界各地的多个项目，该研究已经延长到 2017 年，这些项目统称为全球 ADNI（WW-ADNI）。WW-ADNI 的目标是协调不同地理地点的项目和结果，并鼓励和协调世界各地研究人员的数据管理和可用性。WW-ADNI 项目目前正在北美、欧洲、日本、澳大利亚、韩国、中国台湾和阿根廷进行，中国也有一个初步项目，巴西可能会有一个未来项目。
